[Development of an intravesial oxybutynin chloride solution: from formulation to quality control].
Intravesical oxybutynin chloride has demonstrated its efficacy in children with neurogenic bladder and urinary incontinence refractory to oral anticholinergic agents. We developed a 205 microg/ml oxybutynin chloride solution in accordance with the specifications of the European Pharmacopeae. To guarantee quality, we assessed and validated formulation, the preparation process, and packaging. The solution was obtained by disolving oxybutynin chloride in 0.9% saline and sterile filtration. The solution was then packaged in syringes. Physical properies for intravesical instillation were met: pH 5.76 +/- 0.03, osmolality 281 mosmol/kg. The unit dose package guarantees sterility of the solution until use. The medication is given by adapting the syringe on the Luer Lock exteremity of the urinary catheter. The solution remains stable up to one month at 4 degrees C.
Fratta
A
A
Service de Pharmacie, Hôpital Armand Trousseau, 26, avenue du Docteur Arnold Netter, 75571 Paris Cedex 12.
Bordenave
J
J
Boissinot
C
C
Le Grand
J
J
Esquirol
C
C
Radideau
E
E
Benoit
G
G
D002626:Chemistry, Pharmaceutical; D004355:Drug Stability; D008333:Mandelic Acids / Q000008:administration & dosage* / Q000737:chemistry; D010276:Parasympatholytics / Q000008:administration & dosage* / Q000627:therapeutic use; D019999:Pharmaceutical Solutions; D011786:Quality Control
D008333:Mandelic Acids; D010276:Parasympatholytics; D019999:Pharmaceutical Solutions; C005419:oxybutynin